TheiaNova
PrivateLast Round
SAFE
Apr 30, 2026
Company Overview
TheiaNova operates in Healthcare & Life Sciences and is based in Auckland. Its latest recorded funding round was a Seed round in November 2022.
TheiaNova is a biotechnology company developing a non-surgical, eye-drop treatment to induce therapeutic remodeling of the cornea in patients with ectatic disorders such as keratoconus.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
TheiaNova Comparables
Compare TheiaNova with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| iVeena Delivery Systems | 80% | |
| Epion Therapeutics | 77% | |
| Trefoil Therapeutics | 77% |
For institutional investors. Book with your work email.
TheiaNova Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| SAFE | Apr 30, 2026 | ||||
| VC Round | Apr 4, 2024 | ||||
| Seed | Nov 7, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
TheiaNova Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Callaghan Innovation | Seed |
| Bridgewest Ventures | Seed |
| Auckland UniServices Limited | Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- Nov 7, 2022
Seed round raised with Bridgewest Ventures and Auckland UniServices Limited.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- receives_financingNov 5, 2026
TheiaNova Ltd. extends its $1.5M capital raise on the Snowball Effect platform in Nov '26 after falling slightly short of its target.
- is_developingOct 27, 2026
In New Zealand in Q3 '26, TheiaNova Ltd. is developing novel therapies for people with vision disorders, including a painless, non-invasive treatment for keratoconus based on research from the University of Auckland.
For institutional investors. Book with your work email.
TheiaNova Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about TheiaNova's valuation, stock price, and market status.
Is TheiaNova a public or private company?
TheiaNova is a private company.
What is the current stock price of TheiaNova?
TheiaNova is a private company, so its shares have no public market price. Caplight tracks TheiaNova's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is TheiaNova worth (valuation)?
Valuation information for TheiaNova is not publicly available.
Can I buy TheiaNova stock?
TheiaNova shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was TheiaNova's last funding round?
TheiaNova's most recent funding round was SAFE on April 30, 2026.
Who are the main investors in TheiaNova?
Key investors in TheiaNova include Callaghan Innovation, Bridgewest Ventures, Auckland UniServices Limited.
Will TheiaNova IPO soon?
No public IPO plans have been announced for TheiaNova.
How can I track TheiaNova secondary market activity?
Caplight tracks bids, offers, and trades in TheiaNova's shares on secondary markets.